1. Home
  2. AIRT vs ACET Comparison

AIRT vs ACET Comparison

Compare AIRT & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air T Inc.

AIRT

Air T Inc.

N/A

Current Price

$21.00

Market Cap

63.1M

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

N/A

Current Price

$7.70

Market Cap

69.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIRT
ACET
Founded
1980
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.1M
69.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
AIRT
ACET
Price
$21.00
$7.70
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$65.33
AVG Volume (30 Days)
1.6K
161.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
59.82
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.56
$0.45
52 Week High
$26.70
$9.05

Technical Indicators

Market Signals
Indicator
AIRT
ACET
Relative Strength Index (RSI) 39.79 57.76
Support Level $18.38 $7.70
Resistance Level $24.74 $8.46
Average True Range (ATR) 0.50 0.46
MACD -0.32 -0.01
Stochastic Oscillator 18.79 96.30

Price Performance

Historical Comparison
AIRT
ACET

About AIRT Air T Inc.

Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: